CVRx Posts 20% Revenue Growth in Q1 2026, Launches Key Clinical Trial
Event summary
- Q1 2026 revenue rose 20% YoY to $14.8M, with U.S. revenue up 22% to $13.7M.
- Active implanting centers in the U.S. grew to 257, up from 227 in Q1 2025.
- First patient enrolled in the BENEFIT-HF clinical trial, which could expand Barostim’s patient population threefold.
- Gross margin improved to 87% from 84% YoY, while net loss narrowed slightly to $13.1M.
- Full-year 2026 revenue guidance maintained at $63M–$67M, with gross margin updated to 85%–87%.
The big picture
CVRx’s strong Q1 2026 performance reflects growing adoption of Barostim in the U.S., supported by expanded sales territories and physician awareness. The launch of the BENEFIT-HF trial is critical, as success could triple the device’s addressable patient population. However, sustained growth hinges on managing rising operational costs while navigating a competitive cardiovascular device market.
What we're watching
- Clinical Trial Momentum
- The pace at which BENEFIT-HF enrolls patients will determine Barostim’s expanded market potential.
- U.S. Market Penetration
- Whether CVRx can sustain its 22% U.S. revenue growth amid increasing competition.
- Operational Efficiency
- How rising R&D and SG&A expenses will impact profitability as revenue scales.
Related topics